EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 74 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome September 9, 2019 What can elephants teach us about cancer? August 12, 2023 FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease February 1, 2022 Dress up that Salad! December 21, 2020 Load more HOT NEWS A vision for the next decade of UK life sciences FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... Workout Wednesday – Leg Stretches Part 2 ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ
